本文已被：浏览 971次 下载 334次
投稿时间：2022-07-30 网络发布日期：2022-09-20
投稿时间：2022-07-30 网络发布日期：2022-09-20
中文摘要: 微小残留疾病（MRD）是指在经过针对性和根治性治疗后的肿瘤患者体内检测到的隐匿性微转移或微小残留病灶。通过对乳腺癌MRD进行早期和动态的监测，可以辅助临床治疗决策，实现乳腺癌患者的精准诊疗。随着包括循环肿瘤细胞（CTC）和循环肿瘤DNA （ctDNA）在内的MRD新检测技术的发展，MRD在乳腺癌中的作用也逐渐得到验证，有望成为乳腺癌新的危险分层因素和预后评估指标。本文系统梳理了近年来乳腺癌MRD领域的研究进展，以及面临的机遇和挑战。
Abstract:Minimal residual disease(MRD) refers to the occult micro-metastasis or minimal residual lesions detected in tumor patients after targeted and radical treatment. Early and dynamic monitoring of MRD in breast cancer can assist clinical treatment decision-making and contribute to accurate diagnosis and treatment of breast cancer patients. With the development of new MRD detection technologies including circulating tumor cells and circulating tumor DNA, the role of MRD in breast cancer has been gradually verified, and it is expected to become a new risk stratification factor and prognostic indicator for breast cancer. This paper systematically reviews the research progress, opportunities and challenges in the field of MRD in breast cancer in recent years.
文章编号： 中图分类号：R737.9 文献标志码：A
基金项目:
| Author Name | Affiliation |
| CUI Shi-yun, GUAN Xiao-xiang | Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China |
引用文本：
崔诗允， 管晓翔.乳腺癌微小残留病灶的诊疗进展[J].中国临床研究,2022,35(9):1189-1192.
崔诗允， 管晓翔.乳腺癌微小残留病灶的诊疗进展[J].中国临床研究,2022,35(9):1189-1192.